Antisense Treatment for Thalassemia. Preclinical study.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$588,563.00
Award Year:
2005
Program:
STTR
Phase:
Phase II
Contract:
4R42HL078103-02
Award Id:
71023
Agency Tracking Number:
HL078103
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
P.O. Box 12295, Research Triangle Park, NC, 27709
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RYSZARD KOLE
(919) 966-8207
KOLE@MED.UNC.EDU
Business Contact:
TED BEBENEK
(919) 313-0164
bebenek@ercolebiotech.com
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The ultimate goal of this project is treatment of beta-thalassemia, a genetic blood disease, with antisense oligonucleotides. The project is based on the technology developed by the PI in which antisense oligonucleotides are used to restore correct functioning of a defective gene rather than, as commonly practiced, to inhibit the expression of an undesirable gene. Specifically, oligonucleotides are used to reverse aberrant splicing of human beta-globin pre-mRNA by blocking splice sites activated by a mutation IVS2-654 in intron 2 of the beta-globin gene. Aberrant splicing is also reversed for betaE mutation in exon 1. The oligonucleotides not only inhibit aberrant splicing but, by forcing the spliceosomes to form on the existing correct splice sites, restore correct splicing of beta-globin pre-mRNA, which is translated into the beta-globin polypeptide, ultimately restoring expression of hemoglobin. The main goal of this Phase I proposal is to improve the effectiveness of morpholino oligonucleotides targted to the aberrant IVS2-654 splice site by conjugating them with penetrating tat-like peptides. The proposed work will be carried mostly in erythroid cells from the IVS2-654 mice, in vivo in this mouse model of thalassemia and in cells from thalassemia patients with IVS2-654 thalassemia. The Specific Aims of the project are: 1) To test if morpholino-peptide conjugates effectively correct splicing of beta-globin pre-mRNA and restore expression of hemoglobin in vitro in erythroid cells from IVS2-654 mouse. 2) To test if morpholino-peptide conjugates effectively correct splicing of beta-globin pre-mRNA and restore expression of hemoglobin in vivo in IVS2-654 mouse. 3) To confirm that the most effective oligonucleotides identified in Specific Aims 1 and 2 are effective in erythroid cells from patients with thalassemia.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government